Flexible factory concept allows accelerated drug development and delivery to market
With the addition of MilliporeSigma's Mobius 2000L single-use bioreactor to its new upstream suite at its Biodevelopment Centre in France, the company can now offer clients full process line cGMP manufacturing
MilliporeSigma has expanded its state-of-the art single-use current good manufacturing process (cGMP) facility with the addition of a Mobius 2000L single-use bioreactor. With the new upstream suite at its Biodevelopment Centre in France, MilliporeSigma can now offer clients full process line cGMP manufacturing equipped with its own instrumentation and products.
'Our aim is to facilitate accelerated drug development and delivery via continued innovation and technical expertise by offering customers a complete end-to-end solution from clone to commercial production,' said Udit Batra, CEO of MilliporeSigma.
'Our unique offering gives customers the choice to transfer their production at any stage with the confidence that we will ensure the most efficient transition into commercial manufacturing – at either an existing facility or one we help them design.'
With this increase in scale and scope, the firm can advance recombinant products from cell line development through to late-stage clinical production. At the point of tech transfer to a contract manufacturing organisation or other facility, clients can also leverage MilliporeSigma's Provantage end-to-end services which are available worldwide.
MilliporeSigma's Provantage solution includes process development, cGMP manufacturing, facility design, manufacturing equipment and consumables, process and equipment training, technology transfer and set-up for commercialisation. The offering aims to minimise the risks for customers progressing from early clinical stages to commercial production helping to accelerate time to market and improve productivity and profitability.
Merck's life sciences division operates as MilliporeSigma in the US and Canada and has 19,000 employees and 72 manufacturing sites worldwide, with a portfolio of more than 300,000 products.
Merck completed its $17bn acquisition of Sigma-Aldrich in November 2015.
The Darmstadt, Germany based group operates as EMD Serono, MilliporeSigma and EMD Performance Materials in the US and Canada.